ISIS PHARMACEUTICALS TO RECEIVE HIV ANTISENSE PATENT
ISIS PHARMACEUTICALS TO RECEIVE HIV ANTISENSE PATENT CARLSBAD, Calif., Nov. 10 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIP) announced today that it will be issued a United States patent on antisense oligonulceotide inhibitors of the human immunodeficiency virus (HIV), the virus which also causes AIDS. Pharmaceutical compositions containing these oligonucleotides are also covered in this patent.
The patent, U.S. patent 5,166,195, covers phosphorothiate oligonucleotide compositions designed to selectively bind to RNA encoding the HIV tat protein, blocking replication of the virus and the 5' leader sequence, which is common to all HIV RNA transcripts. "The tat protein has been studied intensely by numerous research groups and is crucial in the life cycle of the AIDS virus. The 5' leader sequence is important because it is present on all HIV transcripts and the compositions targeting this region show exemplary activation," said Dr. Christopher Mirabelli, senior vice president. Isis Pharmaceuticals, Inc., based in northern San Diego County, is engaged in the discovery, development and marketing of novel therapeutic products based on antisense oligonucleotides. Isis is completing Phase I human clinical trials of a new drug, the first antisense drug to be administered to humans, to treat human papillomavirus. -0- 11/10/92 /CONTACT: Christopher Mirabelli, Ph.D., of Isis Pharmaceuticals, Inc., 619-931-9200, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals, Inc./ (ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:
AH-KW -- NY007 -- 9070 11/10/92 08:00 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 10, 1992|
|Previous Article:||PPG, OTHERS, PLAN CHINA FLOAT GLASS PLANT|
|Next Article:||CLARIS ANNOUNCES CLARISWORKS FOR WINDOWS|